Acquired C1-inhibitor deficiency.
Frank
M
M
Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, Maryland 20892.
D000799:Angioedema / Q000188:drug therapy / Q000209:etiology*; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000276:immunology / Q000378:metabolism; D003171:Complement Pathway, Classical; D003613:Danazol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000276:immunology; D008297:Male; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology*
D001323:Autoantibodies; D003174:Complement C1 Inactivator Proteins; D003613:Danazol